Best clinical response to frontline brentuximab vedotin monotherapy
| . | N = 26* . | ||
|---|---|---|---|
| . | n . | % . | 95% CI† . |
| ORR (CR + PR) | 24 | 92 | (74.9, 99.1) |
| Best clinical response | |||
| CR | 19 | 73 | (52.2, 88.4) |
| PR | 5 | 19 | — |
| SD | 2 | 8 | — |
| Disease control rate (CR + PR + SD) | 26 (100) | 100 | (86.9, 100) |